

The statistical analysis of non-linear longitudinal data in biomedical research using generalized additive models

Beyond repeated measures ANOVA and Linear Mixed Models

Ariel I. Mundo¹, John R. Tipton², Timothy J. Muldoon¹²

¹Department of Biomedical Engineering, University of Arkansas, Fayetteville, AR, USA
²Department of Mathematical Sciences, University of Arkansas, Fayetteville, AR, USA

Contents

1	Abstract	2
2	Background	2
3	Challenges presented by longitudinal studies	4
3.1	The repeated measures ANOVA	4
3.2	Linear relationship	5
3.3	Covariance in rm-ANOVA and LMEMs	6
3.4	Missing observations	6
3.5	What does an rm-ANOVA fit looks like? A visual representation using simulated data	7
4	GAMs as a special case of Generalized Linear Models	9
4.1	GAMs and Basis Functions	9
5	The analysis of longitudinal biomedical data using GAMs	12
5.1	Simulated data	12
5.2	An interaction GAM for longitudinal data	12
5.3	Determination of significance in GAMs for longitudinal data	14
6	Conclusion	15
7	References	16
A	Code for Manuscript data	19
A.1	Compound symmetry and independent errors in linear and quadratic responses	19
A.2	Basis functions and GAMs	26

28	B Longitudinal biomedical data simulation and GAMs	30
29	B.1 A basic Workflow for GAMs	32
30	C GAM and Linear model plots and Missing data	40
31	C.1 GAM and Linear model plots	41
32	C.2 Working with Missing data in GAMs	42

1 Abstract

In biomedical research, the outcome of longitudinal studies has been traditionally analyzed using the *repeated measures analysis of variance* (rm-ANOVA) or more recently, a *linear mixed model* (LMEM). Although LMEMs are less restrictive than rm-ANOVA in terms of correlation and missing observations, both methodologies share an assumption of linearity in the measured response, which results in biased estimates and unreliable inference when they are used to analyze data where the trends are non-linear. In contrast, generalized additive models (GAMs), are a class of models that relax the linearity assumption and allow the data to determine the fit of the model while permitting missing observations and different correlation structures, thereby being an excellent choice to analyze non-linear longitudinal data. This paper summarizes the limitations of LMEMs and rm-ANOVA, presents the basic theory of GAMs, and demonstrates their implementation in R via the package *mgcv* using simulated data that follows longitudinal trends reported in biomedical literature. To promote reproducibility in biomedical research, the code and data used to generate this paper are available at:_____.

2 Background

Longitudinal studies are designed to repeatedly measure a variable of interest in a group (or groups) of subjects, with the intention of observing the evolution of effect across time rather than analyzing a single time point (e.g., a cross-sectional study). Biomedical research frequently uses longitudinal studies to analyze the evolution of a “treatment” effect across multiple time points; and in such studies the subjects of analysis range from animals (mice, rats, rabbits), to human patients, cells, or blood samples, among many others. Tumor response [1–4], antibody expression [5,6], and cell metabolism [7,8] are examples of the different situations where researchers have used longitudinal designs to study some physiological response. Because the frequency of the measurements in a longitudinal study is dependent on the biological phenomena of interest and the experimental design of the study, the frequency of such measurements can range from minute intervals to study a short-term response such as anesthesia effects in animals[9], to weekly measurements to analyze a mid-term response like the evolution of dermatitis symptoms in breast cancer patients [10], to monthly measurements to study a long-term response such as mouth opening following radiotherapy (RT) in neck cancer patients [11].

Traditionally, a “frequentist” or “classical” statistical paradigm is used in biomedical research to derive inferences from a longitudinal study. The frequentist paradigm regards probability as the limit of the expected outcome when an experiment is repeated a large number of times [12], and such view is applied to the analysis of longitudinal data by assuming a null hypothesis under a statistical model that is often an *analysis of variance over repeated measures* (repeated measures ANOVA or rm-ANOVA). The rm-ANOVA model makes three key assumptions regarding longitudinal data: 1) linearity of the response across time, 2) constant correlation across same-subject measurements, and 3) observations from each subject are obtained at all time points through the study (a condition also known as *complete observations*) [13,14].

The expected linear behavior of the response through time is a key requisite in rm-ANOVA [15]. This “linearity assumption” in rm-ANOVA implies that the model is misspecified when the data does not follow a linear trend, which results in unreliable inference. In biomedical research, non-linear trends are the norm

rather than the exception in longitudinal studies. A particular example of this non-linear behavior in longitudinal data arises in measurements of tumor response to chemo and/or radiotherapy in preclinical and clinical settings [1,8,16]. These studies have shown that the collected signal does not follow a linear trend over time, and presents extreme variability at different time points, making the fit of rm-ANOVA model inconsistent with the observed variation. Therefore, when rm-ANOVA is used to draw inference of such highly-variable data the estimates are inevitably biased, because the model is only able to accommodate linear trends that are far from adequately representing the biological phenomenon of interest.

A *post hoc* analysis is the statistical test used in conjunction with rm-ANOVA to perform repeated comparisons to estimate a *p-value*, which in turn is used as a measure of significance. Although it is possible that a *post hoc* analysis of rm-ANOVA is able to find “significant” *p-values* ($p < 0.05$) from non-linear data, the validity of such metric is dependent on how adequate the model fits the data. In other words, *p-values* are valid only if the model and the data have good agreement; if that is not the case, a “Type III” error (known as “model misspecification”) occurs[17]. For example, model misspecification will occur when a model that is only able to explain linear responses (such as rm-ANOVA) is fitted to data that follows a quadratic trend, thereby causing the resulting *p-values* and parameter estimates to be invalid [18].

Additionally, the *p-value* itself is highly variable, and multiple comparisons can inflate the false positivity rate (Type I error or α) [19,20], consequently biasing the conclusions of the study. Corrections exist to address the Type I error issue of multiple comparisons (such as Bonferroni [21]), but they in turn reduce statistical power ($1-\beta$)[22], and lead to increased Type II error (failing to reject the null hypothesis when the null hypothesis is false) [23,24]. Therefore, the tradeoff of *post hoc* comparisons in rm-ANOVA between Type I, II and III errors might be difficult to resolve in a biomedical longitudinal study where a delicate balance exists between statistical power and sample size.

On the other hand, the assumption of constant correlation in rm-ANOVA (often known as the *compound symmetry assumption*) is typically unreasonable because correlation between the measured responses often diminishes as the time interval between the observation increases [25]. Corrections can be made in rm-ANOVA in the absence of compound symmetry [26,27], but the effectiveness of the correction is limited by the size of the sample, the number of measurements[28], and group sizes [29]. In the case of biomedical research, where living subjects are frequently used, sample sizes are often not “large” due to ethical and budgetary reasons [30] which might cause the corrections for lack of compound symmetry to be ineffective.

Due to a variety of causes, the number of observations during a study can vary between all subjects. For example, in a clinical trial patients may voluntarily withdraw, whereas attrition due to injury or weight loss in preclinical animal studies is possible. It is even plausible that unexpected complications with equipment or supplies arise that prevent the researcher from collecting measurements at certain time points. In each of these missing data scenarios, the *complete observations* assumption of classical rm-ANOVA is violated. When incomplete observations occur, a rm-ANOVA model is fit by excluding all subjects with missing observations from the analysis [13]. This elimination of partially missing data from the analysis can result in increased costs if the desired statistical power is not met with the remaining observations, because it would be necessary to enroll more subjects. At the same time, if the excluded observations contain insightful information that is not used, their elimination from the analysis may limit the demonstration of significant differences between groups.

During the last decade, the biomedical community has started to recognize the limitations of rm-ANOVA in the analysis of longitudinal information. The recognition on the shortcomings of rm-ANOVA is exemplified by the use of linear mixed effects models (LMEMs) by certain groups to analyze longitudinal tumor response data [8,16]. Briefly, LMEMs incorporate *fixed effects*, which correspond to the levels of experimental factors in the study (e.g., the different drug regimens in a clinical trial), and *random effects*, which account for random variation within the population (e.g., the individual-level differences not due to treatment such as weight or age). When compared to the traditional rm-ANOVA, LMEMs are more flexible as they can accommodate missing observations for multiple subjects and allow different modeling strategies for the variability within each measure in every subject [15]. However, LMEMs impose restrictions in the distribution of the errors of the random effects, which need to be normally distributed and independent [13,31]. And even more importantly, LMEMs also expect a linear relationship between the response and time [15], making them unsuitable to analyze non-linear data.

As the rm-ANOVA and the more flexible LMEM approaches make overly restrictive assumptions regarding the linearity of the response, there is a need for biomedical researchers to explore the use of additional statistical tools that allow the data (and not an assumption in trend) to determine the trend of the fitted model, to enable appropriate inference.

In this regard, generalized additive models (GAMs) present an alternative approach to analyze longitudinal data. Although not frequently used by the biomedical community, these semi-parametric models are customarily used in other fields to analyze longitudinal data. Examples of the use of GAMs include the analysis of temporal variations in geochemical and palaeoecological data [32–34], health-environment interactions [35] and the dynamics of government in political science [36]. There are several advantages of GAMs over LMEMs and rm-ANOVA models: 1) GAMs can fit a more flexible class of smooth responses that enable the data to dictate the trend in the fit of the model, 2) they can model non-constant correlation between repeated measurements [37] and 3) can easily accommodate missing observations. Therefore, GAMs can provide a more flexible statistical approach to analyze non-linear biomedical longitudinal data than LMEMs and rm-ANOVA.

The current advances in programming languages designed for statistical analysis (specifically R), have eased the computational implementation of traditional models such as rm-ANOVA and more complex approaches such as LMEMs and GAMs. In particular, R[38] has an extensive collection of documentation and functions to fit GAMs in the package *mgcv* [37,39] that not only speed up the initial stages of the analysis but also enable the use of advanced modeling structures (e.g. hierarchical models, confidence interval comparisons) without requiring advanced programming skills from the user. At the same time, R has many tools that simplify data simulation, an emerging strategy used to test statistical models [28]. Data simulation methods allow the researcher to create and explore different alternatives for analysis without collecting information in the field, reducing the time window between experiment design and its implementation, and simulation can be also used for power calculations and study design questions.

This work provides biomedical researchers with a clear understanding of the theory and the practice of using GAMs to analyze longitudinal data using by focusing on four areas. First, the limitations of LMEMs and rm-ANOVA regarding linearity of response, constant correlation structures and missing observations is explained in detail. Second, the key theoretical elements of GAMs are presented using clear and simple mathematical notation while explaining the context and interpretation of the equations. Third, using simulated data that reproduces patterns in previously reported studies [16] we illustrate the type of non-linear longitudinal data that often occurs in biomedical research. The simulated data experiments highlight the differences in inference between rm-ANOVA, LMEMs and GAMs on data similar to what is commonly observed in biomedical studies. Finally, reproducibility is emphasized by providing the code to generate the simulated data and the implementation of different models in R, in conjunction with a step-by-step guide demonstrating how to fit models of increasing complexity.

In summary, this work will allow biomedical researchers to identify when the use of GAMs instead of rm-ANOVA or LMEMs is appropriate to analyze longitudinal data, and provide guidance on the implementation of these models by improving the standards for reproducibility in biomedical research.

3 Challenges presented by longitudinal studies

3.1 The repeated measures ANOVA

The *repeated measures analysis of variance* (rm-ANOVA) is the standard statistical analysis for longitudinal data in biomedical research. This statistical methodology requires certain assumptions for the model to be valid. From a practical view, the assumptions can be divided in three areas: 1) linear relationship between covariates and response, 2) a constant correlation between measurements, and, 3) complete observations for all subjects. Each one of these assumptions is discussed below.

3.2 Linear relationship

3.2.1 The repeated measures ANOVA case

In a longitudinal biomedical study, two or more groups of subjects (e.g., human subject, mice, samples) are subject to different treatments (e.g., a “treatment” group receives a novel drug or intervention vs. a “control” group that receives a placebo), and measurements from each subject within each group are collected at specific time points. The collected response is modeled with *fixed* components. The *fixed* component can be understood as a constant value in the response which the researcher is interested in measuring, i.e., the average effect of the novel drug/intervention in the “treatment” group.

Mathematically speaking, a rm-ANOVA model with an interaction can be written as:

$$y_{ijt} = \beta_0 + \beta_1 \times time_t + \beta_2 \times treatment_j + \beta_3 \times time_t \times treatment_j + \varepsilon_{ijt} \quad (1)$$

In this model y_{ijt} is the response for subject i , in treatment group j at time t , which can be decomposed in a mean value β_0 , *fixed effects* of time ($time_t$), treatment ($treatment_j$) and their interaction $time_t * treatment_j$ which have linear slopes given by β_1, β_2 and β_3 , respectively. Independent errors ε_{ijt} represent random variation not explained by the *fixed* effects, and are assumed to be $\sim N(0, \sigma^2)$ (independently normally distributed with mean zero and variance σ^2). In a biomedical research context, suppose two treatment groups are used in a study (e.g., “placebo” vs. “novel drug” or “saline” vs. “chemotherapy”). Then, the group terms in Equation (1) can be written as below with $treatment_j = 0$ representing the first treatment group (Group A) and $treatment_j = 1$ representing the second treatment group (Group B). The linear models then can be expressed as

$$y_{ijt} = \begin{cases} \beta_0 + \beta_1 \times time_t + \varepsilon_{ijt} & \text{if Group A} \\ \beta_0 + \beta_2 + \beta_1 \times time_t + \beta_3 \times time_t + \varepsilon_{ijt} & \text{if Group B} \end{cases} \quad (2)$$

To further simplify the expression, substitute $\widetilde{\beta}_0 = \beta_0 + \beta_2$ and $\widetilde{\beta}_1 = \beta_1 + \beta_3$ in the equation for Group B. This substitution allows for a different intercept and slope for Groups A and B. The model is then written as

$$y_{ijt} = \begin{cases} \beta_0 + \beta_1 \times time_t + \varepsilon_{ijt} & \text{if Group A} \\ \widetilde{\beta}_0 + \widetilde{\beta}_1 \times time_t + \varepsilon_{ijt} & \text{if Group B} \end{cases} \quad (3)$$

Presenting the model in this manner makes clear that when treating different groups, an rm-ANOVA model is able to accommodate non-parallel lines in each case (different intercepts and slopes per group). In other words, the rm-ANOVA model “expects” a linear relationship between the covariates and the response, this means that either presented as Equation (1), Equation (2) or Equation (3), an rm-ANOVA model is only able to accommodate linear patterns in the data. If the data show non-linear behavior, the rm-ANOVA model will approximate this behavior with non-parallel lines.

3.2.2 The Linear Mixed Model Case

A linear mixed model (LMEM) is a class of statistical model that incorporates *fixed effects* to model the relationship between the covariates and the response, and *random effects* to model subject variability that is not the primary focus of the study but that might be important to distinguish [15,40]. A LMEM with interaction between time and treatment for a longitudinal study can be written as:

$$y_{ijt} = \beta_0 + \beta_1 \times time_t + \beta_2 \times treatment_j + \beta_3 \times time_t \times treatment_j + \mu_{ij} + \varepsilon_{ijt} \quad (4)$$

When Equation (1) and Equation (4) are compared, it is easily noticeable that LMEM and rm-ANOVA have the same construction regarding the *fixed effects* of time and treatment, but that the LMEM incorporates an additional source of variation (the term μ_{ij}). This term μ_{ij} is the one that corresponds to the *random effect*, accounting for variability in each subject within each group. The *random* component can also be understood as used to model some “noise” in the response, but that is intended to be analyzed and disentangled from the “global noise” term ε_{ijt} from Equation (1).

For example, if the blood concentration of the drug is measured in certain subjects in the early hours of the morning while other subjects are measured in the afternoon, it is possible that the difference in the collection time introduces some “noise” in the data. As the name suggests, this “random” variability needs to be modeled as a variable rather than as a constant value. The *random effect* μ_{ij} in Equation (4) is assumed to be $\mu_{ij} \sim N(0, \sigma_\mu^2)$. In essence, the *random effect* in a LMEM enables to fit models with different slopes at the subject-level [15]. However, the expected linear relationship of the covariates and the response in Equation (1) and in Equation (4) is essentially the same, representing a major limitation of LMEMs to fit a non-linear response.

3.3 Covariance in rm-ANOVA and LMEMs

In a longitudinal study there is an expected *covariance* between repeated measurements on the same subject, and because repeated measures occur in the subjects within each group, there is a *covariance* between measurements at each time point within each group. The *covariance matrix* (also known as the variance-covariance matrix) is a matrix that captures the variation between and within subjects in a longitudinal study [41] (For an in-depth analysis of the covariance matrix see [40,42]).

In the case of an rm-ANOVA analysis, it is typically assumed that the covariance matrix has a specific construction known as *compound symmetry* (also known as “sphericity” or “circularity”). Under this assumption, the between-subject variance and within-subject correlation are constant across time [26,42,43]. However, it has been shown that this condition is frequently not justified because the correlation between measurements tends to change over time [44]; and it is higher between consecutive measurements [13,25]. Although corrections can be made (such as Huynh-Feldt or Greenhouse-Geisser) [26,27] the effectiveness of each correction is limited because it depends on the size of the sample, the number of repeated measurements [28], and they are not robust if the group sizes are unbalanced [29]. Because biomedical longitudinal studies are often limited in sample size and can have an imbalanced design, the corrections required to use an rm-ANOVA model may not be able to provide a reasonable adjustment that makes the model valid.

In the case of LMEMs, one key advantage over rm-ANOVA is that they allow different structures for the variance-covariance matrix including exponential, autoregressive of order 1, rational quadratic and others [15]. Nevertheless, the analysis required to determine an appropriate variance-covariance structure for the data can be a challenging process by itself. Overall, the spherical assumption for rm-ANOVA may not capture the natural variations of the correlation in the data, and can bias the inferences from the analysis.

3.4 Missing observations

Missing observations are an issue that arises frequently in longitudinal studies. In biomedical research, this situation can be caused by reasons beyond the control of the investigator [45]. Dropout from patients and attrition or injury in animals are among the reasons for missing observations. Statistically, missing information can be classified as *missing at random* (MAR), *missing completely at random* (MCAR), and *missing not at random* (MNAR) [42]. In a MAR scenario, the pattern of the missing information is related to some variable in the data, but it is not related to the variable of interest [46]. If the data are MCAR, this means that the missingness is completely unrelated to the collected information [47], and in the case of MNAR the missing values are dependent on their value. An rm-ANOVA model assumes complete observations for all subjects, and therefore subjects with one or more missing observations are excluded from the analysis. This is inconvenient because the remaining subjects might not accurately represent the population, and statistical power is affected by this reduction in sample size [48].

In the case of LMEMs, inferences from the model are valid when missing observations in the data exist that are MAR or MCAR [40]. For example, if attrition occurs in all mice that had lower weights at the beginning of a chemotherapy response study, the missing data can be considered MAR because the missigness is unrelated to other variables of interest.

This section has presented the assumptions for analyzing longitudinal data using rm-ANOVA and LMEMs and compared their differences regarding linearity, the covariance matrix and missing data. In particular, LMEMs offer a more robust and flexible approach than rm-ANOVA and if the data follows a linear trend, they provide an excellent choice to derive inferences from a repeated measures study. However, when the data presents high a non-linear behavior, LMEMs and rm-ANOVA fail to capture the trend of the data. To better convey the issues of linearity and correlation in linear models fitted to non-linear data, simulation is used in the next section.

3.5 What does an rm-ANOVA fit looks like? A visual representation using simulated data

To demonstrate the limitations of rm-ANOVA an LMEMs for non-linear longitudinal data, this section presents a simulation experiment of a normally distributed response of two groups of 10 subjects each. An rm-ANOVA model (Equation (1)) is fitted to each group, using R[38] and the package *nlme*[49]. Briefly, two cases for the mean responses for each group are considered: in the first case, the mean response in each group is a linear function with different intercepts and slopes; a negative slope is used for Group 1 and a positive slope is used for Group 2 (Figure 1, A). In the second case, a second-degree polynomial (quadratic) function is used for the mean response per group: the quadratic function is concave down for Group 1 and it is concave up for Group 2 (Figure 1, C). In both the linear and quadratic simulated data, the groups start with the same mean value at the first time point. This is intentional in order to simulate the expected temporal evolution of some physiological quantity.

Specifically, the rationale for the chosen linear and quadratic functions is the likelihood that a measured response in two treatment groups is similar in the initial phase of the study, but as treatment progresses a divergence in the trend of the response indicates an effect due to treatment. In other words, Group 1 can be thought as a “Control” group and Group 2 as a “Treatment” group. From the mean response per group (linear or quadratic), the variability or “error” of individual responses within each group is simulated using a covariance matrix with compound symmetry (constant variance across time). Thus, the response per subject in both the linear and quadratic simulation corresponds to the mean response per group plus the error (Figure 1 B,D). A more comprehensive exploration of the fit of rm-ANOVA for linear and non-linear longitudinal appears in Figure 5 and Figure 6 in the Appendix, where simulation with compound symmetry and independent errors (errors generated from a normal distribution that are not constant over time) and the plot of simulated errors, and fitted parameters in presented.




Figure 1: Simulated linear responses from two groups with correlated (top row) or independent (bottom row) errors using a rm-ANOVA model. A, C: Simulated data with known mean response (linear or quadratic, thin lines) and individual responses (points) showing the dispersion of the data. B, D: Estimates from the rm-ANOVA model for the mean group response (linear or quadratic). Thick lines are the predicted mean response per group, thin lines are the random effects for each subject and points represent the original raw data. The rm-ANOVA model not only fails to pick the trend of the quadratic data but it also incorrectly estimates the initial conditions.

The simulation shows that the fit produced by the rm-ANOVA model is good for linear data, as the predictions for the mean response are reasonably close to the “truth” of the simulated data (Figure 1, B). When the linearity and compound symmetry assumptions are met, the model approximates well the individual trends and the mean trends by group.

However, consider the case when the data follows a non-linear trend, such as the simulated data in Figure 1, C. Here, the mean response per group was simulated using a quadratic function but errors, individual responses and the rm-ANOVA model were produced in the same manner as in (Figure 1 A and B). The mean response in the simulated data with quadratic behavior is changing in each group through the timeline, and the mean value is the same as the initial value by the fifth time point for each group. Fitting an rm-ANOVA model (1) to this data produces the fit that appears in panel D in Figure 1.

A comparison of the fitted mean response of the rm-ANOVA model to the the simulated data in Figure ((1, D) indicates that the model is not capturing the changes within each group in a good way. Specifically, note that the fitted mean response of the rm-ANOVA model (panel D) shows that the change (increase for Treatment 1 or decrease for Treatment 2) in the response through time points 2 and 4 is not being captured by the model. Moreover, the rm-ANOVA model is not being able to capture the fact that the initial values are the same in each group, and instead fits non-parallel lines that have initial values that are

markedly different from the “true” initial values in each case (compare panels C and D). If such change has important physiological implications, the rm-ANOVA model omits it from the fitted mean response. Thus, even though the model correctly detects a difference in treatment groups, the exact nature of this difference is not correctly identified, limiting valuable inferences from the data.

This section has used simulation to better convey the limitations of linearity and correlation in the response in non-linear data. Although the model fitted to the simulated data was an rm-ANOVA model, the main issue of an expected linear trend in the response is the same in the case of a LMEM. In the following section, we present generalized additive models (GAMs) as a data-driven alternative method to analyze longitudinal non-linear data.

4 GAMs as a special case of Generalized Linear Models

4.1 GAMs and Basis Functions

Generalized linear models (GLMs) are a family of models that fit a linear response function to data that do not have normally distributed errors[50]. In contrast, GAMs are a family of regression-based methods for estimating smoothly varying trends and are a broader class of models that contain the GLM family as a special case[34,37,51]. A GAM model can be written as:

$$y_{ijt} = \beta_0 + f(x_t | \beta_j) + \varepsilon_{ijt} \quad (5)$$

Where y_{ijt} is the response at time t of subject i in group j , β_0 is the expected value at time 0, the change of y_{ijt} over time is represented by the function $f(x_t | \beta_j)$ with inputs as the covariates x_t and parameters β_j , and ε_{ijt} represents the residual error.

In contrast to the linear functions used to model the relationship between the covariates and the response in rm-ANOVA or LMEM, GAMs use more flexible *smooth functions*. This approach is advantageous as it does not restrict the model to a linear relationship, although a GAM will estimate a linear relationship if the data is consistent with a linear response. One possible set of functions for $f(x_t | \beta_j)$ that allow for non-linear responses are polynomials, but a major limitation is that polynomials create a “global” fit as they assume that the same relationship exists everywhere, which can cause problems with the fit [36]. In particular, polynomial fits are known to show boundary effects because as t goes to $\pm\infty$, $f(x_t | \beta_j)$ goes to $\pm\infty$ which is almost always unrealistic, and causes bias at the endpoints of the time period.

The smooth functional relationship between the covariates and the response in GAMs is specified using a semi-parametric relationship that can be fit within the GLM framework, by using *basis functions* expansions of the covariates and by estimating random coefficients for these basis functions. A *basis* is a set of functions that spans the space where the smooths that approximate $f(x_t | \beta_j)$ exist [34]. For the linear model in Equation (1), the basis coefficients are β_1 , β_2 and β_3 and the basis vectors are $time_t$, $treatment_j$ and $time_t \times treatment_j$. The basis function then, is the combination of basis coefficients and basis vectors that map the possible relationship between the covariates and the response [52], which in the case of Equation (1) is restricted to a linear family of functions. In the case of Equation (5), the basis function is $f(x_t | \beta_j)$, which means that the model allows for non-linear relationships among the covariates.

A commonly used *basis function* is the cubic spline, which is a smooth curve constructed from cubic polynomials joined together in a manner that enforces smoothness [34,37]. Cubic splines have a long history in solving semi-parametric statistical problems and are often a default choice to fit GAMs as they are a simple, flexible and powerful option to obtain smoothness [53]. Therefore, this data-driven flexibility in GAMs overcomes the limitation that occurs in LMEMs and rm-ANOVA when the data is non linear.

To further clarify the concept of basis functions and smooth functions, consider the simulated response for Group 1 in Figure (1, C). The simplest GAM model that can be used to estimate such response is that of a single smooth term for the time effect; i.e., a model that fits a smooth to the trend of the group through time.

The timeline can be divided in equally spaced *knots*, each knot being a region where a different basis function will be used. Because there are six timepoints for this group, five knots can be used. The model with five knots to construct the smooth term means that it will have four basis functions (plus one that corresponds to the intercept). The choice of basis functions is already optimized in the package *mgcv* depending on the number of knots. In Panel A of Figure 2, the four basis functions (and the intercept) are shown. Each of the basis functions is composed of six different points (because there are six points on the timeline). To control the “wigliness” of the fit, each of the basis functions of Panel A is penalized by multiplying it by a coefficient according to the penalty matrix of Panel B. The penalty reduces the “wigliness” of the smooth fit to prevent overfitting: A weak penalty estimate will result in wiggly functions whereas a strong penalty estimate provides evidence that a linear response is appropriate.

In other words, the six points of each basis are multiplied by the corresponding coefficient in panel B, thereby increasing or decreasing the original basis functions of Panel A. In Figure 2, Panel C shows the resulting penalized basis functions. Note that the penalization for basis 1 has resulted in a decrease of its overall value (because the coefficient for that basis function is negative and less than 1); on the other hand, basis 3 has roughly doubled its value. Finally, the penalized basis functions are added at each timepoint to produce the smooth term. The resulting smooth term for the effect of *time* is shown in Panel D (orange line) along the simulated values per group, which appear as points.




Figure 2: Basis functions for a single smoother for time with five knots. A: Basis functions for a single smoother for time for the simulated data of Group 1 from Figure 2, the intercept basis is not shown. B: Penalty matrix for the basis functions. Each basis function is penalized by a coefficient which can be positive or negative. The coefficient determines the overall effect of each basis in the final smoother. C: Penalized basis functions. Each of the four basis functions of panel A has been penalized by the corresponding coefficient shown in Panel B, note the corresponding increase (or decrease) of each basis. D: Smoother for time and original data points. The smoother (line) is the result of the sum of each penalized basis function at each time point, simulated values for the group appear as points.

5 The analysis of longitudinal biomedical data using GAMs

The previous sections provided the basic theoretical framework to understand the GAM framework and how these models are more advantageous to analyze non-linear longitudinal data when compared to LMEMs or rm-ANOVA. This section will use simulation to present the practical implementation of GAMs for longitudinal biomedical data using R and the package `mgcv`. The code for the simulated data and figures, and a brief guide for model selection and diagnostics appear in the Appendix.

5.1 Simulated data

The simulated data is based on the reported longitudinal changes in oxygen saturation (StO_2) in subcutaneous tumors that appear in Figure 3(C) in [16]. In the paper, diffuse reflectance spectroscopy was used to quantify StO_2 changes in both groups at the same time points (days 0, 2, 5, 7 and 10). In the “Treatment” group (chemotherapy) an increase in StO_2 is observed through time, while a decrease is seen in the “Control” (saline) group. Following the reported trend, we simulated 10 normally distributed observations at each time point with a standard deviation (SD) of 10% (matching the SD in the original paper). The simulated and real data appear in Figure 3, A and the inset, respectively.

5.2 An interaction GAM for longitudinal data

An interaction model is typically the main interest in longitudinal biomedical data, as it takes into account the effect of treatment, time, and their combination. In a practical sense, when a GAM is implemented for longitudinal data, a smooth can be added to the model for the *time* effect to account for the repeated measures over time. Although specific methods of how GAMs model correlation structures is a topic beyond the scope of this paper, it suffices to say that GAMs are flexible and can handle correlation structures beyond compound symmetry. A detailed description on basis functions and correlations can be found in [52].

For the data in Figure 3,A it is of interest to know the effect that each treatment has in StO_2 . The model then needs to incorporate independent smooths for *Group* and *Day*, respectively. The main thing to consider is that model syntax accounts for the fact that one of the variables is numeric (*Day*) and the other is a factor (*Group*). Because the smooths are centered at 0, the factor variable needs to be specified as a parametric term in order to identify any differences between the groups. Using R and the package `mgcv` the model syntax is:

```
m1<-gam(StO2_sim~Group+s(Day,by=Group,k=5,bs="gp"), method='REML',data=dat_sim)
```

This syntax specifies that `m1` will store the model, and that the change in the simulated oxygen saturation (`StO2_sim`) is modeled using independent smooths for *Group* and *Day* (the parenthesis preceded by *s*) using 5 knots. The smooth is constructed using gaussian process smooths, which is indicated by `bs="gp"`. These splines are used to model temporal trends and might be particularly suited for long-term studies where the correlation between measurements changes as a function of the time intervals [34]. The parametric term *Group* is added to quantify differences in the effect of treatment between groups, and the `method` chosen to select the smoothing parameters is the restricted maximum likelihood (REML) [37]. When the smooths are plotted over the raw data, it is clear that the model has been able to capture the trend of the change of StO_2 for each group across time (Figure 3,B). Model diagnostics can be obtained using the `gam.check` function, and the function `appraise` from the package *gratia*[54]. A guide for model selection and diagnostics is in the Appendix, and an in-depth analysis can be found in [37] and [55].

One question that might arise at this point is “what is the fit that an rm-ANOVA model produces for the simulated data?” The rm-ANOVA model, which corresponds to Equation (1) is presented in Figure 3,C. This is a typical case of model misspecification: The slopes of each group are different, which would lead to a *p-value* indicating significance for the treatment and time effects, but the model is not capturing the changes that occur at days 2 and between days 5 and 7, whereas the GAM model is able to do so (Figure 3,B) .

Because GAMs do not require equally-spaced or complete observations for all subjects, they are advantageous to analyze longitudinal data where missingness exists. The rationale behind this is that GAMs are able to pick the trend in the data even when some observations are missing. However, this usually causes the resulting smooths to have wider confidence intervals and less ability to pick certain trends. Consider the simulated StO_2 values from Figure (3, B). If 40% of the total observations are randomly deleted and the same interaction GAM fitted for the complete dataset is used, the resulting smooths are still able to show a different trend for each group, but the “Treatment” smooth takes an overall more linear profile (3, D). Although the confidence intervals have increased for both smooths, the model still shows different trends with as little as 4 observations per group at certain time points.




Figure 3: Simulated data and smooths for oxygen saturation in tumors. A: Simulated data that follows previously reported trends (inset) in tumors under chemotherapy (Treatment) or saline (Control) treatment. Simulated data is from a normal distribution with standard deviation of 10% with 10 observations per time point. Lines indicate mean oxygen saturation B: Smooths from the GAM model for the full simulated data with interaction of Group and Treatment. Lines represent trends for each group, shaded regions are 95% confidence intervals. C: rm-ANOVA model for the simulated data, the model does not capture the changes in each group over time. D: Smooths for the GAM model for the simulated data with 40% of its observations missing. Lines represent trends for each group, shaded regions are 95% confidence intervals.




Figure 4: Pairwise comparisons for smooth terms. A: Pairwise comparisons for the full dataset. B: Pairwise comparisons for the dataset with missing observations. Significant differences exist where the interval does not cover 0. In both cases the effect of treatment is significant after day 5.

5.3 Determination of significance in GAMs for longitudinal data

At the core of a biomedical longitudinal study lies the question of a significant difference between the effect of two or more treatments in different groups. Whereas in *rm*-ANOVA a *post-hoc* analysis is required to answer such question by calculating some *p-values* after multiple comparisons, GAMs can use a different approach to estimate significance. In essence, the idea behind the estimation of significance in GAMs across different treatment groups is that if the *difference* between the confidence intervals of the fitted smooths for such groups is non-zero, then a significant difference exists at that time point(s). The absence of a *p-value* in this case might seem odd, but the confidence interval comparison can be conceptualized in the following manner: Different trends in each group are an indication of an effect by the treatment. This is what happens for the simulated data in Figure 3, A where the chemotherapy causes StO₂ to increase over time.

With this expectation of different trends in each group, computing the difference between the trends will identify if the observed change is significant. The difference between groups with similar trends is likely to yield zero, which would indicate that the treatment is not causing a change in the response in one of the groups (assuming the other group is a Control or Reference group).

Consider the calculation of pairwise differences for the smooths in 3 B and D. Figure 4, shows the comparison between each treatment group. Here, the effect of the “Control” group is compared to that of the “Treatment” group. The shaded region under the curve highlights the interval where each group has a higher effect than the other. Notice that the shaded region between days 0 and 4 indicates that through that time, the “Control” group has higher StO₂, but as therapy progresses the effect is reversed and by day 5 it is the “Treatment” group the one that has greater contribution. This would suggest that the effect of chemotherapy is significant after day 5 for the model used; which is noticeable in the data with missing observations albeit the missing data model has a wider confidence interval and is not able to pick the change between days 7 and 10 that the full dataset model is able to detect.

6 Conclusion

The traditional methods to analyze biomedical longitudinal data (rm-ANOVA, LMEMs) are restricted to cases when the data follows a linear pattern. When the trend of the data is non-linear (as it is frequently the case in biomedical research), the use of rm-ANOVA and LMEMs leads to unreliable inference and biased estimates. GAMs present a suitable alternative to analyze non-linear longitudinal biomedical data, as they overcome the limitations of linearity, compound symmetry, and missing observations imposed by traditional methods. By presenting in a clear and visual manner the limitations of rm-ANOVA and LMEMs, and the implementation of GAMs using simulated data that follows previously reported trends in the literature, we aim at encouraging biomedical researchers to consider different statistical tools to analyze longitudinal data. Finally, by providing the data and code used in this paper we hope to address the need of creating and sharing reproducible work in biomedical research.

7 References

- [1] D. Roblyer, S. Ueda, A. Cerussi, W. Tanamai, A. Durkin, R. Mehta, D. Hsiang, J.A. Butler, C. McLaren, W.P. Chen, B. Tromberg, Optical imaging of breast cancer oxyhemoglobin flare correlates with neoadjuvant chemotherapy response one day after starting treatment, *Proceedings of the National Academy of Sciences of the United States of America*. 108 (2011) 14626–14631. <https://doi.org/10.1073/pnas.1013103108>.
- [2] A. Tank, H.M. Peterson, V. Pera, S. Tabassum, A. Leproux, T. O’Sullivan, E. Jones, H. Cabral, N. Ko, R.S. Mehta, B.J. Tromberg, D. Roblyer, Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens, *Breast Cancer Research*. 22 (2020) 1–10. <https://doi.org/doi:10.1186/s13058-020-01262-1>.
- [3] M.V. Pavlov, T.I. Kalganova, Y.S. Lyubimtseva, V.I. Plekhanov, G.Y. Golubyatnikov, O.Y. Ilyinskaya, A.G. Orlova, P.V. Subochev, D.V. Safonov, N.M. Shakhova, A.V. Maslennikova, Multimodal approach in assessment of the response of breast cancer to neoadjuvant chemotherapy, *Journal of Biomedical Optics*. 23 (2018). <https://doi.org/%7B10.1117/1.JBO.23.9.091410%7D>.
- [4] V. Demidov, A. Maeda, M. Sugita, V. Madge, S. Sadanand, C. Flueraru, I.A. Vitkin, Preclinical longitudinal imaging of tumor microvascular radiobiological response with functional optical coherence tomography, *Scientific Reports*. 8 (2018). <https://doi.org/%7B10.1038/s41598-017-18635-w%7D>.
- [5] G. Ritter, L. Cohen, C. Williams, E. Richards, L. Old, S. Welt, Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33, *Cancer Research*. 61 (2001) 6851–6859.
- [6] E.M. Roth, A.C. Goldberg, A.L. Catapano, A. Torri, G.D. Yancopoulos, N. Stahl, A. Brunet, G. Lecorps, H.M. Colhoun, Antidrug Antibodies in Patients Treated with Alirocumab, *New England Journal of Medicine*. 376 (2017) 1589–1590. <https://doi.org/%7B10.1056/NEJMc1616623%7D>.
- [7] J.D. Jones, H.E. Ramser, A.E. Woessner, K.P. Quinn, In vivo multiphoton microscopy detects longitudinal metabolic changes associated with delayed skin wound healing, *Communications Biology*. 1 (2018). <https://doi.org/%7B10.1038/s42003-018-0206-4%7D>.
- [8] M.C. Skala, A. Fontanella, L. Lan, J.A. Izatt, M.W. Dewhirst, Longitudinal optical imaging of tumor metabolism and hemodynamics, *Journal of Biomedical Optics*. 15 (2010). <https://doi.org/10.1117/1.3285584>.
- [9] G.J. Greening, K.P. Miller, C.R. Spainhour, M.D. Cato, T.J. Muldoon, Effects of isoflurane anesthesia on physiological parameters in murine subcutaneous tumor allografts measured via diffuse reflectance spectroscopy, *Biomedical Optics Express*. 9 (2018) 2871–2886. <https://doi.org/%7B10.1364/BOE.9.002871%7D>.
- [10] T.T. Sio, P.J. Atherton, B.J. Birkhead, D.J. Schwartz, J.A. Sloan, D.K. Seisler, J.A. Martenson, C.L. Loprinzi, P.C. Griffin, R.F. Morton, J.C. Anders, T.J. Stoffel, R.E. Haselow, R.B. Mowat, M.A.N. Wittich, J.D. Bearden III, R.C. Miller, Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]), *Supportive Care in Cancer*. 24 (2016) 3847–3855. <https://doi.org/%7B10.1007/s00520-016-3213-3%7D>.
- [11] J.I. Kamstra, P.U. Dijkstra, M. van Leeuwen, J.L.N. Roodenburg, J.A. Langendijk, Mouth opening in patients irradiated for head and neck cancer: A prospective repeated measures study, *Oral Oncology*. 51 (2015) 548–555. <https://doi.org/%7B10.1016/j.oraloncology.2015.01.016%7D>.
- [12] E.-J. Wagenmakers, M. Lee, T. Lodewyckx, G.J. Iverson, Bayesian versus frequentist inference, in: H. Hoijtink, I. Klugkist, P.A. Boelen (Eds.), *Bayesian Evaluation of Informative Hypotheses*, Springer New York, New York, NY, 2008: pp. 181–207. https://doi.org/10.1007/978-0-387-09612-4_9.

- [13] R. Gueorguieva, J.H. Krystal, Move over ANOVA - Progress in analyzing repeated-measures data and its reflection in papers published in the archives of general psychiatry, *Archives of General Psychiatry*. 61 (2004) 310–317. <https://doi.org/10.1001/archpsyc.61.3.310>.
- [14] P. Schober, T.R. Vetter, Repeated measures designs and analysis of longitudinal data: If at first you do not succeed-try, try again, *Anesthesia and Analgesia*. 127 (2018) 569–575. <https://doi.org/10.1213/ane.0000000000003511>.
- [15] J. Pinheiro, D. Bates, *Mixed-effects models in S and S-PLUS*, Springer Science & Business Media, 2006. <https://doi.org/https://doi.org/10.1007/b98882>.
- [16] K. Vishwanath, H. Yuan, W.T. Barry, M.W. Dewhirst, N. Ramanujam, Using optical spectroscopy to longitudinally monitor physiological changes within solid tumors, *Neoplasia*. 11 (2009) 889–900. <https://doi.org/10.1593/neo.09580>.
- [17] B. Dennis, J.M. Ponciano, M.L. Taper, S.R. Lele, Errors in Statistical Inference Under Model Misspecification: Evidence, Hypothesis Testing, and AIC, *Frontiers in Ecology and Evolution*. 7 (2019). <https://doi.org/%7B10.3389/fevo.2019.00372%7D>.
- [18] B. Wang, Z. Zhou, H. Wang, X.M. Tu, C. Feng, The p-value and model specification in statistics, *General Psychiatry*. 32 (2019). <https://doi.org/%7B10.1136/gpsych-2019-100081%7D>.
- [19] C. Liu, T.P. Cripe, M.-O. Kim, Statistical issues in longitudinal data analysis for treatment efficacy studies in the biomedical sciences, *Molecular Therapy*. 18 (2010) 1724–1730. <https://doi.org/10.1038/mt.2010.127>.
- [20] L.G. Halsey, D. Curran-Everett, S.L. Vowler, G.B. Drummond, The fickle P value generates irreproducible results, *Nature Methods*. 12 (2015) 179–185. <https://doi.org/%7B10.1038/nmeth.3288%7D>.
- [21] H. Abdi, Holm’s Sequential Bonferroni Procedure, *Encyclopedia of Research Design*. 1 (2010) 1–8. <https://doi.org/10.4135/9781412961288.n178>.
- [22] S. Nakagawa, A farewell to Bonferroni: the problems of low statistical power and publication bias, *Behavioral Ecology*. 15 (2004) 1044–1045. <https://doi.org/%7B10.1093/beheco/arh107%7D>.
- [23] A. Gelman, J. Hill, M. Yajima, Why We (Usually) Don’t Have to Worry About Multiple Comparisons, *Journal of Research on Educational Effectiveness*. 5 (2012) 189–211. <https://doi.org/%7B10.1080/19345747.2011.618213%7D>.
- [24] C. Albers, The problem with unadjusted multiple and sequential statistical testing, *Nature Communications*. 10 (2019). <https://doi.org/%7B10.1038/s41467-019-09941-0%7D>.
- [25] C. Ugrinowitsch, G.W. Fellingham, M.D. Ricard, Limitations of ordinary least squares models in analyzing repeated measures data, *Medicine and Science in Sports and Exercise*. 36 (2004) 2144–2148. <https://doi.org/10.1249/01.mss.0000147580.40591.75>.
- [26] H. Huynh, L.S. Feldt, Estimation of the box correction for degrees of freedom from sample data in randomized block and split-plot designs, *Journal of Educational Statistics*. 1 (1976) 69–82. <https://doi.org/10.3102/10769986001001069>.
- [27] S.W. Greenhouse, S. Geisser, On methods in the analysis of profile data, *Psychometrika*. 24 (1959) 95–112. <https://doi.org/10.1007/bf02289823>.
- [28] N. Haverkamp, A. Beauducel, Violation of the Sphericity Assumption and Its Effect on Type-I Error Rates in Repeated Measures ANOVA and Multi-Level Linear Models (MLM), *Frontiers in Psychology*. 8 (2017). <https://doi.org/%7B10.3389/fpsyg.2017.01841%7D>.

- [29] H. Keselman, J. Algina, R. Kowalchuk, The analysis of repeated measures designs: A review, *British Journal of Mathematical & Statistical Psychology*. 54 (2001) 1–20. <https://doi.org/10.1348/0007110011593577D>.
- [30] Jaykaran. Charan, N. Kantharia, How to calculate sample size in animal studies?, *Journal of Pharmacology and Pharmacotherapeutics*. 4 (2013) 303–306. <https://doi.org/10.4103/0976-500X.119726>.
- [31] D.J. Barr, R. Levy, C. Scheepers, H.J. Tily, Random effects structure for confirmatory hypothesis testing: Keep it maximal, *Journal of Memory and Language*. 68 (2013) 255–278. <https://doi.org/10.1016/j.jml.2012.11.0017D>.
- [32] N.L. Rose, H.D. Yang, S.D. Turner, G.L. Simpson, An assessment of the mechanisms for the transfer of lead and mercury from atmospherically contaminated organic soils to lake sediments with particular reference to Scotland, UK, *Geochimica Et Cosmochimica Acta*. 82 (2012) 113–135. <https://doi.org/10.1016/j.gca.2010.12.026>.
- [33] E.J. Pedersen, D.L. Miller, G.L. Simpson, N. Ross, Hierarchical generalized additive models in ecology: An introduction with mgcv, *PeerJ*. 7 (2019). <https://doi.org/10.7717/peerj.6876>.
- [34] G.L. Simpson, Modelling palaeoecological time series using generalised additive models, *Frontiers in Ecology and Evolution*. 6 (2018). <https://doi.org/10.3389/fevo.2018.00149>.
- [35] L. Yang, G. Qin, N. Zhao, C. Wang, G. Song, Using a generalized additive model with autoregressive terms to study the effects of daily temperature on mortality, *BMC Medical Research Methodology*. 12 (2012). <https://doi.org/10.1186/1471-2288-12-1657D>.
- [36] N. Beck, S. Jackman, Beyond linearity by default: Generalized additive models, *American Journal of Political Science*. (1998) 596–627.
- [37] S.N. Wood, *Generalized additive models: An introduction with*, second edition, CRC Press LLC, Philadelphia, PA, 2017.
- [38] R Core Team, *R: A language and environment for statistical computing*, R Foundation for Statistical Computing, Vienna, Austria, 2020. <https://www.R-project.org/>.
- [39] S.N. Wood, N. Pya, B. Saeften, Smoothing Parameter and Model Selection for General Smooth Models, *Journal of the American Statistical Association*. 111 (2016) 1548–1563. <https://doi.org/10.1080/01621459.2016.11809867D>.
- [40] B.T. West, K.B. Welch, A.T. Galecki, *Linear mixed models: A practical guide using statistical software*, second edition, Taylor & Francis, 2014. <https://books.google.com/books?id=hjT6AwAAQBAJ>.
- [41] R.D. Wolfinger, Heterogeneous variance: Covariance structures for repeated measures, *Journal of Agricultural, Biological, and Environmental Statistics*. 1 (1996) 205–230. <http://www.jstor.org/stable/1400366>.
- [42] R.E. Weiss, *Modeling longitudinal data*, Springer New York, 2005. https://books.google.com/books?id=MQ/_bvWDPsEAC.
- [43] S. Geisser, S.W. Greenhouse, An Extension of Box’s Results on the Use of the F Distribution in Multivariate Analysis, *The Annals of Mathematical Statistics*. 29 (1958) 885–891. <https://doi.org/10.1214/aoms/1177706545>.
- [44] S.E. Maxwell, H.D. Delaney, K. Kelley, *Designing experiments and analyzing data: A model comparison perspective*, third edition, Taylor & Francis, 2017. <https://books.google.com/books?id=NmFQDwAAQBAJ>.

- [45] G. Molenberghs, H. Thijs, I. Jansen, C. Beunckens, M. Kenward, C. Mallinckrodt, R. Carroll, Analyzing incomplete longitudinal clinical trial data, *Biostatistics*. 5 (2004) 445–464. <https://doi.org/10.1093/biostatistics/kxh001>.
- [46] J. Scheffer, Dealing with missing data, *Research Letters in the Information and Mathematical Sciences*. 3 (2002) 153–160.
- [47] R.F. Potthoff, G.E. Tudor, K.S. Pieper, V. Hasselblad, Can one assess whether missing data are missing at random in medical studies?, *STATISTICAL METHODS IN MEDICAL RESEARCH*. 15 (2006) 213–234. <https://doi.org/10.1191/0962280206sm448oa>.
- [48] Y. Ma, M. Mazumdar, S.G. Memtsoudis, Beyond Repeated-Measures Analysis of Variance Advanced Statistical Methods for the Analysis of Longitudinal Data in Anesthesia Research, *Regional Anesthesia and Pain Medicine*. 37 (2012) 99–105. <https://doi.org/10.1097/AAP.0b013e31823ebc74>.
- [49] J. Pinheiro, D. Bates, S. DebRoy, D. Sarkar, R Core Team, nlme: Linear and nonlinear mixed effects models, 2020. <https://CRAN.R-project.org/package=nlme>.
- [50] J.A. Nelder, R.W.M. Wedderburn, Generalized linear models, *Journal of the Royal Statistical Society. Series A (General)*. 135 (1972) 370–384. <http://www.jstor.org/stable/2344614>.
- [51] T. Hastie, R. Tibshirani, Generalized additive models: Some applications, *Journal of the American Statistical Association*. 82 (1987) 371–386. <https://doi.org/10.1080/01621459.1987.10478440>.
- [52] T.J. Hefley, K.M. Broms, B.M. Brost, F.E. Buderman, S.L. Kay, H.R. Scharf, J.R. Tipton, P.J. Williams, M.B. Hooten, The basis function approach for modeling autocorrelation in ecological data, *ECOLOGY*. 98 (2017) 632–646. <https://doi.org/10.1002/ecy.1674>.
- [53] E.J. Wegman, I.W. Wright, Splines in statistics, *Journal of the American Statistical Association*. 78 (1983) 351–365. <https://doi.org/10.1080/01621459.1983.10477977>.
- [54] G.L. Simpson, Gratia: Graceful 'ggplot'-based graphics and other functions for GAMs fitted using 'mgcv', 2020. <https://CRAN.R-project.org/package=gratia>.
- [55] J. Harezlak, D. Ruppert, M.P. Wand, Semiparametric regression with r, Springer New York, 2018. <https://doi.org/10.1007/978-1-4939-8853-2>.

A Code for Manuscript data

This section presents the code used to generate figures, models and simulated data from Sections 3 and 4 from the main manuscript.

A.1 Compound symmetry and independent errors in linear and quadratic responses

This section simulated linear and quadratic data in the same manner as in Section 3.5. The linear simulations using Figure 5 show in panels A and D the simulated mean responses and individual data points. Panels C and G show a visual interpretation of “correlation” in the responses: In panel C, subjects that have a value of the random error ε either above or below the mean group response are more likely to have other observations that follow the same trajectory, thereby demonstrating correlation in the response. In panel G, because the errors are independent, there is no expectation that responses are likely to follow a similar pattern. Panels D and H show the predictions from the rm-ANOVA model.

The following code produces a more comprehensive exploration of Figure 1 in the main manuscript.

```

570 #####Section for calculations
571 #####
572 #
573 #####
574
575
576 ## Example with linear response
577
578 #This function simulates data using a linear or quadratic mean response
579 and each with correlated
580 #or uncorrelated errors. Each group has a different slope/concavity.
581 example <- function(n_time = 6, #number of time points
582                     fun_type = "linear", #type of response
583                     error_type = "correlated") {
584
585     if (!(fun_type %in% c("linear", "quadratic")))
586       stop('fun_type must be either "linear", or "quadratic"')
587     if (!(error_type %in% c("correlated", "independent")))
588       stop('fun_type must be either "correlated", or "independent"')
589
590
591     x <- seq(1,6, length.out = n_time)
592
593     #Create mean response matrix: linear or quadratic
594     mu <- matrix(0, length(x), 2)
595     # linear response
596     if (fun_type == "linear") {
597       mu[, 1] <- - (0.25*x)+2
598       mu[, 2] <- 0.25*x+2
599     } else {
600       # quadratic response (non-linear)
601
602       mu[, 1] <- -(0.25 * x^2) +1.5*x-1.25
603       mu[, 2] <- (0.25 * x^2) -1.5*x+1.25
604     }
605
606     #create an array where individual observations per each time point for
607     each group are to be stored. Currently using 10 observations per
608     timepoint
609     y <- array(0, dim = c(length(x), 2, 10))
610
611     #Create array to store the "errors" for each group at each timepoint.
612     The "errors" are the
613     #between-group variability in the response.
614     errors <- array(0, dim = c(length(x), 2, 10))
615     #create an array where 10 observations per each time point for each
616     group are to be stored
617
618     #The following cycles create independent or correlated responses. To
619     each value of mu (mean response per group) a randomly generated error
620     (correlated or uncorrelated) is added and thus the individual
621     response is created.
622     if (error_type == "independent") {

```

```

624   ## independent errors
625   for (i in 1:2) {
626     for (j in 1:10) {
627       errors[, i, j] <- rnorm(6, 0, 0.25)
628       y[, i, j] <- mu[, i] + errors[, i, j]
629     }
630   }
631 } else {
632   for (i in 1:2) {      # number of treatments
633     for (j in 1:10) {   # number of subjects
634       # compound symmetry errors: variance covariance matrix
635       errors[, i, j] <- rmvn(1, rep(0, length(x)), 0.1 * diag(6) + 0.25
636         * matrix(1, 6, 6))
637       y[, i, j] <- mu[, i] + errors[, i, j]
638     }
639   }
640 }
641
642
643 ## subject random effects
644
645 ## visualizing the difference between independent errors and compound
646   symmetry
647 ## why do we need to account for this -- overly confident inference
648
649 #labelling y and errors
650   dimnames(y) <- list(time = x,
651     treatment = 1:2,
652     subject = 1:10)
653
654   dimnames(errors) <- list(time = x,
655     treatment = 1:2,
656     subject = 1:10)
657
658 #labeling the mean response
659   dimnames(mu) <- list(time = x,
660     treatment = 1:2)
661
662 #convert y, mu and errors to dataframes with time, treatment and
663   subject columns
664   dat <- as.data.frame.table(y,
665     responseName = "y")
666   dat_errors <- as.data.frame.table(errors,
667     responseName = "errors")
668   dat_mu <- as.data.frame.table(mu,
669     responseName = "mu")
670
671 #join the dataframes to show mean response and errors per subject
672   dat <- left_join(dat, dat_errors,
673     by = c("time", "treatment", "subject"))
674   dat <- left_join(dat, dat_mu,
675     by = c("time", "treatment"))
676 #add time
677   dat$time <- as.numeric(as.character(dat$time))

```

```

678 #label subjects per group
679 dat <- dat %>%
680   mutate(subject = factor(paste(subject,
681                                 treatment,
682                                 sep = "-")))
683
684
685 ## repeated measures ANOVA in R
686 #time and treatment interaction model, compound symmetry required by the
687 model
688 fit_lme <- lme(y ~ treatment + time + treatment:time,
689               data = dat,
690               random = ~ 1 | subject,
691               correlation = corCompSymm(form = ~ 1 | subject)
692 )
693
694 #create a prediction frame where the model can be used for plotting
695 purposes
696 pred_dat <- expand.grid(
697   treatment = factor(1:2),
698   time = unique(dat$time)
699 )
700
701 #add model predictions to the dataframe that has the simulated data
702 dat$y_pred <- predict(fit_lme)
703
704 #return everything in a list
705 return(list(
706   dat = dat,
707   pred_dat = pred_dat,
708   fit_lme = fit_lme
709 ))
710 }
711
712 #####Section for plotting#####
713 #####
714 #This function will create the plots for either a "linear" or "quadratic"
715 response
716
717 plot_example <- function(sim_dat) {
718   ## Plot the simulated data (scatterplot)
719   p1 <- sim_dat$dat %>%
720     ggplot(aes(x = time,
721                y = y,
722                group = treatment,
723                color = treatment)
724           ) +
725     geom_point(show.legend=FALSE) +
726     labs(y='response')+
727     geom_line(aes(x = time,
728                   y = mu,
729                   color = treatment),
730              show.legend=FALSE) +
731     theme_classic() +

```

```

732   theme(plot.title = element_text(size = 30,
733                                   face = "bold"),
734         text=element_text(size=30))+
735   scale_color_aaas()
736
737 #plot the simulated data with trajectories per each subject
738 p2 <- sim_dat$dat %>%
739   ggplot(aes(x = time,
740             y = y,
741             group = subject,
742             color = treatment)
743         ) +
744   geom_line(aes(size = "Subjects"),
745            show.legend = FALSE) +
746   # facet_wrap(~ treatment) +
747   geom_line(aes(x = time,
748               y = mu,
749               color = treatment,
750               size = "Simulated Truth"),
751            lty = 1, show.legend = FALSE) +
752   labs(y='response')+
753   scale_size_manual(name = "Type", values=c("Subjects" = 0.5, "Simulated
754       Truth" = 3)) +
755   theme_classic()+
756   theme(plot.title = element_text(size = 30,
757                                   face = "bold"),
758         text=element_text(size=30))+
759   scale_color_aaas()
760
761 #plot the errors
762 p3 <- sim_dat$dat %>%
763   ggplot(aes(x = time,
764             y = errors,
765             group = subject,
766             color = treatment)) +
767   geom_line(show.legend=FALSE) +
768   labs(y='errors')+
769   theme_classic()+
770   theme(plot.title = element_text(size = 30,
771                                   face = "bold"),
772         text=element_text(size=30))+
773   scale_color_aaas()
774
775 #plot the model predictions
776 p4 <- ggplot(sim_dat$dat,
777             aes(x = time,
778               y = y,
779               color = treatment)) +
780   geom_point()+
781   labs(y='response')+
782   geom_line(aes(y = predict(sim_dat$fit_lme),
783                 group = subject, size = "Subjects")) +
784   geom_line(data = sim_dat$pred_dat,
785             aes(y = predict(sim_dat$fit_lme,

```

```

786         level = 0,
787         newdata = sim_dat$pred_dat),
788         size = "Population")) +
789     scale_size_manual(name = "Predictions",
790                       values=c("Subjects" = 0.5, "Population" = 3)) +
791     theme_classic() +
792     theme(plot.title = element_text(size = 30,
793                                     face = "bold"),
794           text=element_text(size=30))+
795     scale_color_aaas()
796
797     return((p1+p3+p2+p4)+plot_layout(nrow=1)+plot_annotation(tag_levels = 'A
798                          '))
799
800 }
801
802
803 txt<-18
804
805 #Store each plot in a separate object
806 A1<-plot_example(example(fun_type = "linear", error_type = "correlated"))
807
808 B1<-plot_example(example(fun_type = "linear", error_type = "independent"))
809
810 C1<-plot_example(example(fun_type = "quadratic", error_type = "correlated"
811                          ))
812
813 D1<-plot_example(example(fun_type = "quadratic", error_type = "independent
814                          "))
815

```





Figure 5: Simulated linear responses from two groups with correlated (top row) or independent (bottom row) errors using a rm-ANOVA model. A, C: Simulated data with known mean response (linear or quadratic, thin lines) and individual responses (points) showing the dispersion of the data. B, D: Estimations from the rm-ANOVA model for the mean group response (linear or quadratic). Thick lines are the predicted mean response per group, thin lines are the random effects for each subject and points represent the original raw data. The rm-ANOVA model does not pick the trend of the quadratic data.

816 For the quadratic response case, Figure 6 shows the simulated responses using compound symmetry and
817 independent errors.




Figure 6: Simulated quadratic responses from two groups with a rm-ANOVA model fitted. A,E: Simulated data with known mean response (lines) and individual responses (points) showing the dispersion of the data. B,F: Generated errors showing the difference in the behavior of correlated and independent errors. C,G: Simulated known response per group (thick lines) with individual trajectories (thin lines), note that subjects with observations in the area above the mean response tend to stay in that region through the timeline. D,H: Estimations from the rm-ANOVA model for the mean group response. Thick lines are the predicted mean response per group, thin lines are the random effects for each subject and points represent the original raw data.

A.2 Basis functions and GAMs

This code produces Figure 2 from the main manuscript. Briefly, a non-linear (quadratic) response is simulated a gam model is fitted and the basis are extracted in order to explain how the smooth is constructed. The code for data simulation is used again here for the sake of keeping the same structure, although the data can be simulated in a more simple fashion.

```
#generate the response: the same initial procedure from the previous
#section to simulate
#the response
n_time = 6
x <- seq(1,6, length.out = n_time)
mu <- matrix(0, length(x), 2)
mu[, 1] <- -(0.25 * x^2) + 1.5*x - 1.25 #mean response
mu[, 2] <- (0.25 * x^2) - 1.5*x + 1.25 #mean response
y <- array(0, dim = c(length(x), 2, 10))
```

```

833 errors <- array(0, dim = c(length(x), 2, 10))
834 for (i in 1:2) { # number of treatments
835   for (j in 1:10) { # number of subjects
836     # compound symmetry errors
837     errors[, i, j] <- rmvn(1, rep(0, length(x)), 0.1 * diag(6) + 0.25
838       * matrix(1, 6, 6))
839     y[, i, j] <- mu[, i] + errors[, i, j]
840   }
841 }
842
843 #label each table
844 dimnames(y) <- list(time = x, treatment = 1:2, subject = 1:10)
845 dimnames(errors) <- list(time = x, treatment = 1:2, subject = 1:10)
846 dimnames(mu) <- list(time = x, treatment = 1:2)
847
848 #Convert to dataframes with subject, time and group columns
849 dat <- as.data.frame.table(y, responseName = "y")
850 dat_errors <- as.data.frame.table(errors, responseName = "errors")
851 dat_mu <- as.data.frame.table(mu, responseName = "mu")
852 dat <- left_join(dat, dat_errors, by = c("time", "treatment", "subject"))
853 dat <- left_join(dat, dat_mu, by = c("time", "treatment"))
854 dat$time <- as.numeric(as.character(dat$time))
855
856 #label subject per group
857 dat <- dat %>%
858   mutate(subject = factor(paste(subject, treatment, sep = "-")))
859
860 #extract "Group 1" to fit the GAM
861 dat<-subset(dat,treatment==1)
862 #keep just the response and timepoint columns
863 dat<-dat[,c('y','time')]
864
865 #GAM model of time, 5 knots
866 gm<-gam(y~s(time,k=5),data=dat)
867
868 #model_matrix (also known as) 'design matrix'
869 #will contain the smooths used to create model 'gm'
870 model_matrix<-as.data.frame(predict(gm,type='lpmatrix'))
871
872
873 time<-c(1:6)
874
875 basis<-model_matrix[1:6,] #extracting basis (because the values are
876   repeated after every 6 rows)
877 #basis<-model_matrix[1:6,-1] #extracting basis
878 colnames(basis)[colnames(basis)=="(Intercept)"]<-s(time).0"
879 basis<-basis %>% #pivoting to long format
880   pivot_longer(
881     cols=starts_with("s")
882   )%>%
883   arrange(name) #ordering
884
885 #length of dataframe to be created: number of knots by number of
886   timepoints (minus 1 for the intercept that we won't plot)

```

```

887 ln<-6*(length(coef(gm)))
888
889 basis_plot<-data.frame(Basis=integer(ln),
890                        value_orig=double(ln),
891                        time=integer(ln),
892                        cof=double(ln)
893 )
894
895 basis_plot$time<-rep(time) #pasting timepoints
896 basis_plot$Basis<-factor(rep(c(1:5),each=6)) #pasting basis number values
897 basis_plot$value_orig<-basis$value #pasting basis values
898 basis_plot$cof<-rep(coef(gm)[1:5],each=6) #pasting coefficients
899 basis_plot<-basis_plot%>%
900   mutate(mod_val=value_orig*cof) #the create the predicted values the
901   bases need to be
902 #multiplied by the coefficients
903
904 #creating labeller to change the labels in the basis plots
905
906 basis_names<-c(
907   '1'="Intercept",
908   '2'="1",
909   '3'="2",
910   '4'="3",
911   '5'="4"
912 )
913
914 #calculating the final smooth by aggregating the basis functions
915
916 smooth<-basis_plot%>%
917   group_by(time)%>%
918   summarize(smooth=sum(mod_val))
919
920
921 #original basis
922 sz<-1
923 p11<-ggplot(basis_plot,
924             aes(x=time,
925                 y=value_orig,
926                 colour=as.factor(Basis)
927             )
928             )+
929   geom_line(size=sz,
930             show.legend=FALSE)+
931   geom_point(size=sz+1,
932              show.legend = FALSE)+
933   labs(y='Basis functions')+
934   facet_wrap(~Basis,
935              labeller = as_labeller(basis_names)
936              )+
937   theme_classic()+
938   scale_color_aaas()
939
940

```

```

941 #penalized basis
942 p12<-ggplot(basis_plot,
943             aes(x=time,
944                 y=mod_val,
945                 colour=as.factor(Basis)
946             )
947         )+
948     geom_line(show.legend = FALSE,
949              size=sz)+
950     geom_point(show.legend = FALSE,
951               size=sz+1)+
952     labs(y='Penalized \n basis functions')+
953     scale_y_continuous(breaks=seq(-1,1,1))+
954     facet_wrap(~Basis,
955               labeller=as_labeller(basis_names)
956             )+
957     theme_classic()+
958     scale_color_aaas()
959
960 #heatmap of the penalization coefficient
961 x_labels<-c("Intercept","1","2","3","4")
962 p13<-ggplot(basis_plot,
963             aes(x=Basis,
964                 y=Basis,
965                 fill=cof))+
966     geom_tile(aes(color='black'),
967              size=sz+1,
968              show.legend = FALSE)+
969     geom_tile(size=sz+1)+
970     scale_fill_gradient(low = "white", high = "red")+
971     labs(x='Basis',
972          y='Basis')+
973     scale_x_discrete(labels=x_labels)+
974     geom_text(aes(label=round(cof,2)),
975              size=10,
976              show.legend = FALSE)+
977     theme_classic()+
978     theme(legend.title = element_blank())
979
980 #plotting simulated datapoints and smooth term
981 p14<-ggplot(data=dat,
982             aes(x=time,y=y))+
983     geom_point(size=sz+1)+
984     scale_color_aaas()+
985     labs(y='Simulated \n response')+
986     geom_line(data=smooth,
987              aes(x=time,
988                  y=smooth),
989              color="#B15731",
990              size=sz+1)+
991     theme_classic()
992
993
994 #Combining all

```

```

995 b_plot<-p11+p13+p12+p14+plot_annotation(tag_levels='A')&
996   theme(
997     text=element_text(size=18)
998   )
999

```




Figure 7: Basis functions for a single smoother for time with five knots. A: Basis functions for a single smoother for time for the simulated data of Group 1 from Figure 2, the intercept basis is not shown. B: Penalty matrix for the basis functions. Each basis function is penalized by a coefficient which can be positive or negative. The coefficient determines the overall effect of each basis in the final smoother. C: Penalized basis functions. Each of the four basis functions of panel A has been penalized by the corresponding coefficient shown in Panel B, note the corresponding increase (or decrease) of each basis. D: Smoother for time and original data points. The smoother (line) is the result of the sum of each penalized basis function at each time point, simulated values for the group appear as points.

B Longitudinal biomedical data simulation and GAMs

This section describes how to fit GAMs to longitudinal data using simulated data. First, data is simulated according to Section 5, where reported data of oxygen saturation (StO_2) in tumors under either chemotherapy or saline control is used as a starting point to generate individual responses in each group.

```

1004 #Dataframe that contains the original reported trends
1005 dat<-tibble(StO2=c(4,27,3,2,0.5,7,4,50,45,56),
1006             Day=rep(c(0,2,5,7,10),times=2),
1007

```

```

1008         Group=as.factor(rep(c("Control","Treatment"),each=5))
1009     )
1010
1011
1012     ## plot the mean response
1013     f1<-ggplot(dat,
1014               aes(x = Day,
1015                   y = St02,
1016                   color = Group)) +
1017       geom_line(size=1,
1018                 show.legend = FALSE)+
1019       geom_point(show.legend = FALSE,
1020                 size=1.5,
1021                 alpha=0.5)+
1022       labs(y=expression(paste(St0[2],
1023                               ' (real)')))+
1024       theme_classic()+
1025       scale_color_aaas()+
1026       scale_x_continuous(breaks=c(0,5,10))+
1027       scale_y_continuous(breaks=c(0,40))+
1028       plot_layout(tag_level = 'new')+
1029       theme(
1030         plot.background = element_rect(fill = "transparent",
1031                                         color = NA),
1032         axis.text=element_text(size=14)
1033       )
1034
1035
1036     #This function simulates data for the tumor data using default parameters
1037     #of 10 observations per time point, and Standard deviation (sd) of 5%.
1038     #Because physiologically St02 cannot go below 0%, data is generated with
1039     #a cutoff value of 0.0001 (the "St02_sim")
1040
1041     simulate_data <- function(dat, n = 10, sd = 5) {
1042       dat_sim <- dat %>%
1043         slice(rep(1:n(), each = n)) %>%
1044         group_by(Group, Day) %>%
1045         mutate(
1046           St02_sim = pmax(rnorm(n, St02, sd), 0.0001),
1047           subject=rep(1:10),
1048           subject=factor(paste(subject, Group, sep = "-"))
1049         ) %>%
1050         ungroup()
1051
1052       return(dat_sim)
1053     }
1054
1055
1056     #subject = factor(paste(subject, treatment, sep = "-"))
1057
1058     n <- 10 #number of observations
1059     sd <- 10 #approximate sd from paper
1060     set.seed(1) #set seed for reproducibility
1061     df <- 6

```

```

1062 dat_sim <- simulate_data(dat, n, sd)
1063
1064 #plotting simulated data
1065 f2<-ggplot(dat_sim,
1066           aes(x = Day,
1067               y = StO2_sim,
1068               color = Group)) +
1069   geom_point(show.legend=FALSE,
1070             size=1.5,
1071             alpha=0.5)+
1072   stat_summary(aes(y = StO2_sim,
1073                   group=Group),
1074               fun=mean, geom="line",
1075               size=1,
1076               show.legend = FALSE)+
1077   labs(y=expression(atop(StO2["2"],
1078                         '(simulated)')))+
1079   theme_classic()+
1080   theme(
1081     axis.text=element_text(size=22)
1082   )+
1083   scale_color_aas()+
1084   scale_x_continuous(breaks=c(0,2,5,7,10))
1085

```

1086 B.1 A basic Workflow for GAMs

1087 This section shows a basic workflow to fit a series of increasingly complex GAMs to the simulated data from
 1088 the previous section. Graphical and parameter diagnostics for goodness of fit are discussed, as well as model
 1089 comparison via AIC (Aikake Information Criterion).

1090 B.1.1 First model

1091 The first model fitted to the data is one that only accounts for different smooths by day. The model syntax
 1092 specifies that `gam_00` is the object that will contain all the model information, and that the model attempts
 1093 to explain changes in `StO2_sim` (simulated StO₂) using a smooth per `Day`. The model will use 5 knots (`k=5`)
 1094 for the smooth. And that the smooth is constructed using gaussian process basis (`bs="gp"`). The smoothing
 1095 parameter estimation method used is the restricted maximum likelihood (REML).

```

1096
1097 gam_00<-gam(StO2_sim ~ s(Day, k = 5,bs="gp"),
1098            method='REML',
1099            data = dat_sim)
1100

```

1101 To obtain model diagnostics, two methodologies are to be used: 1) graphical diagnostics, and 2) a model
 1102 check. In the first case, the functions `appraise` and `draw` from the package *gratia* can be used to obtain
 1103 a single output with all the graphical diagnostics. For model check, the functions `gam.check` and `summary`
 1104 from *mgcv* provide detailed information about the model fit and its parameters.

1105 B.1.1.1 Graphical diagnostics

```

1106 ## Error: The given dimensions cannot hold all panels. Please increase '
1107 ncol' or 'nrow'
1108


```


Figure 8: Graphical diagnostics for the first GAM model. Left: Graphical diagnostics provided by the function `appraise` from the package *gratia*. Right: Fitted smooth for the model, provided by the function `draw`.

1109 From the output of the function `appraise` in Figure 8, the major indicators of concern about the model
 1110 are the QQ plot of residuals and the histogram of residuals. The QQ plot shows that the errors are not
 1111 reasonably located along the 45° line (which indicates normality), as there are multiple points that deviate
 1112 from the trend, specially in the tails. The histogram also shows that the variation (residuals) is not following
 1113 the assumption of a normal distribution.

1114 The `draw` function permits to plot the smooths as `ggplot2` objects, which eases subsequent manipulation, if
 1115 desired. Because model `gam_00` specifies only one smooth for the time covariate (Day), the plot only contains
 1116 only one smooth. Note that the smooth shows an almost linear profile.

1117 **B.1.1.2 Model check**
 1118 #need to add figure number and caption
 1119 `gam.check(gam_00)`
 1120



```

1121
1122 ##
1123 ##
1124 ## Method: REML   Optimizer: outer newton
1125 ## full convergence after 6 iterations.
1126 ## Gradient range [-4.142968e-08,2.799316e-12]
1127 ## (score 440.4108 & scale 414.2575).
1128 ## Hessian positive definite, eigenvalue range [0.04576008,49.0005].
1129 ## Model rank =  5 / 5
1130 ##
1131 ## Basis dimension (k) checking results. Low p-value (k-index<1) may
1132 ## indicate that k is too low, especially if edf is close to k'.
1133 ##
1134 ##           k'   edf k-index p-value
1135 ## s(Day) 4.00 1.31    0.26  <2e-16 ***
1136 ## ---
1137 ## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
1138

```

```

1139
1140 summary(gam_00)
1141

```

```

1142 ##
1143 ##
1144 ## Family: gaussian
1145 ## Link function: identity
1146 ##
1147 ## Formula:
1148 ## StO2_sim ~ s(Day, k = 5, bs = "gp")
1149 ##
1150 ## Parametric coefficients:

```

```

1151 ##           Estimate Std. Error t value Pr(>|t|)
1152 ## (Intercept)    21.929      2.035   10.77  <2e-16 ***
1153 ## ---
1154 ## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
1155 ##
1156 ## Approximate significance of smooth terms:
1157 ##           edf Ref.df      F p-value
1158 ## s(Day)  1.314  1.536  9.151 0.00253 **
1159 ## ---
1160 ## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
1161 ##
1162 ## R-sq.(adj) =  0.105   Deviance explained = 11.7%
1163 ## -REML = 440.41   Scale est. = 414.26      n = 100
1164

```

1165 Special attention must be paid to the ‘k-index’ from `gam.check`. This parameter indicates if the basis
1166 dimension of the smooth is adequate, i.e., it checks that the basis used to create the smooth are adequate
1167 to capture the trends in the data. If the model is not adequately capturing the trends in the data, this is
1168 indicated by a low k-index value (<1). From the output, it can be seen that the k-index is effectively <0.3 ,
1169 which indicates that the model is not capturing the variability in the data. The ‘edf’ (effective degrees of
1170 freedom) is an indicator of the complexity of the smooth. Here the complexity of the smooth is comparable
1171 to that of a 4th degree polynomial.

1172 From the `summary` function, information about the assumed distribution of the errors (Gaussian in this
1173 case) and the link function can be obtained. The link function is ‘identity’ as the model does not make
1174 any transformation on the predictors. The ‘significance of smooth terms’ *p-value* indicates if each smooth
1175 is adding significance to the model. Here, the *p-value* is low but we have seen that there are issues with
1176 the model from the previous outputs. Finally, the ‘deviance explained’ indicates how much of the data the
1177 model is able to capture, which in this case corresponds to $\sim 12\%$.


1178 B.1.2 Second model

1179 The major flaw of `gam_00` is that this model is not taking into account the fact that the data is nested in
1180 groups. The next iteration is a model where a different smooth of time (Day) is assigned for each group
1181 using `by=Group` in the model syntax.

```

1182 gam_01<-gam(St02_sim ~ s(Day, by=Group, k = 5, bs="gp"),
1183             method='REML',
1184             data = dat_sim)
1185
1186
1187 gam.check(gam_01)
1188

```



```

1189
1190 ##
1191 ## Method: REML   Optimizer: outer newton
1192 ## full convergence after 10 iterations.
1193 ## Gradient range [-0.0001703751,9.561998e-05]
1194 ## (score 418.612 & scale 270.7177).
1195 ## Hessian positive definite, eigenvalue range [0.0001702821,48.50255].
1196 ## Model rank = 9 / 9
1197 ##
1198 ##
1199 ## Basis dimension (k) checking results. Low p-value (k-index<1) may
1200 ## indicate that k is too low, especially if edf is close to k'.
1201 ##
1202 ##           k'   edf k-index p-value
1203 ## s(Day):GroupControl  4.00 1.00   0.32 <2e-16 ***
1204 ## s(Day):GroupTreatment 4.00 1.72   0.32 <2e-16 ***
1205 ## ---
1206 ## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
1207

```

```

1208
1209 summary(gam_01)
1210
1211 ##
1212 ## Family: gaussian
1213 ## Link function: identity
1214 ##
1215 ## Formula:
1216 ## StO2_sim ~ s(Day, by = Group, k = 5, bs = "gp")
1217 ##
1218

```

```

1219 ## Parametric coefficients:
1220 ##           Estimate Std. Error t value Pr(>|t|)
1221 ## (Intercept)    21.929      1.645   13.33  <2e-16 ***
1222 ## ---
1223 ## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
1224 ##
1225 ## Approximate significance of smooth terms:
1226 ##           edf Ref.df      F p-value
1227 ## s(Day):GroupControl    1.001   1.001   4.099   0.0456 *
1228 ## s(Day):GroupTreatment  1.715   1.979  35.551  <2e-16 ***
1229 ## ---
1230 ## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
1231 ##
1232 ## R-sq.(adj) =  0.415   Deviance explained = 43.1%
1233 ## -REML = 418.61   Scale est. = 270.72      n = 100
1234

```

1235 Diagnostics for this model indicate that the k-index is still below 1 (0.32 from `gam.check`), and that the
1236 residuals are still not following a normal distribution (Figure 9). Moreover, the smooths (plotted via the
1237 `draw()` function) appear with a fairly linear profile, which indicates they are still not capturing the trends
1238 observed in the data. From `summary()`, the deviance explained by the model is ~43%.

```

1239 ## Error: The given dimensions cannot hold all panels. Please increase '
1240 ncol' or 'nrow'
1241
1242

```


Figure 9: Graphical diagnostics for the second GAM model. Left: Graphical diagnostics provided by the function `appraise` from the package *gratia*. Right: Fitted smooth for the model, provided by the function `draw`.

1243 B.1.3 Third model

1244 Model `gam_00` was built for didactic purposes to cover the simplest case, but it does not account for the
1245 nesting of the data by Group, which is apparent from the type of smooth fitted, the model diagnostics, and,

the low variance explained by the model. On the other hand, `gam_01` takes into account the nesting within each group and provides better variance explanation, but as indicated in Section 5, in order to differentiate between each group a parametric term needs to be added to the model for the interaction of *Day* and *Group*.

```
#GAM for St02
gam1 <- gam(St02_sim ~ Group+s(Day, by = Group, k = 5,bs="gp"),
            method='REML',
            data = dat_sim)
gam.check(gam1)
```



```
##
## Method: REML   Optimizer: outer newton
## full convergence after 9 iterations.
## Gradient range [-1.003557e-07,3.562136e-08]
## (score 362.7587 & scale 64.03804).
## Hessian positive definite, eigenvalue range [0.9494021,48.08513].
## Model rank = 10 / 10
##
## Basis dimension (k) checking results. Low p-value (k-index<1) may
## indicate that k is too low, especially if edf is close to k'.
##
##          k'   edf k-index p-value
## s(Day):GroupControl  4.00 3.83   1.02   0.52
## s(Day):GroupTreatment 4.00 3.84   1.02   0.59
```

```

1275
1276 summary(gam1)
1277
1278
1279 ##
1280 ## Family: gaussian
1281 ## Link function: identity
1282 ##
1283 ## Formula:
1284 ## St02_sim ~ Group + s(Day, by = Group, k = 5, bs = "gp")
1285 ##
1286 ## Parametric coefficients:
1287 ##             Estimate Std. Error t value Pr(>|t|)
1288 ## (Intercept)    9.781      1.132    8.643 1.85e-13 ***
1289 ## GroupTreatment 24.296      1.600   15.181 < 2e-16 ***
1290 ## ---
1291 ## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
1292 ##
1293 ## Approximate significance of smooth terms:
1294 ##             edf Ref.df      F p-value
1295 ## s(Day):GroupControl  3.825  3.971 16.81 <2e-16 ***
1296 ## s(Day):GroupTreatment 3.835  3.974 78.84 <2e-16 ***
1297 ## ---
1298 ## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
1299 ##
1300 ## R-sq.(adj) =  0.862   Deviance explained = 87.4%
1301 ## -REML = 362.76   Scale est. = 64.038      n = 100
1302
1303 The resulting model is model gam1, which is the model fitted in the main manuscript. By using appraise()
1304 and draw on this model (Figure 10) we see that the trend on the QQ plot has improved, the histogram of the
1305 residuals appears to be reasonably distributed, and the smooths are capturing the trend of the data within
1306 each group . From gam.check, the k-index is now at an acceptable value (~1.02), and summary now indicates
1307 that the model is able to capture 87% of the variance data.
1308
1309 ## Error: The given dimensions cannot hold all panels. Please increase '
1310 ncol' or 'nrow'
1311

```

Figure 10: Graphical diagnostics for the final GAM model. Left: Graphical diagnostics provided by the function `appraise` from the package *gratia*. Right: Fitted smooths for the model, provided by the function `draw`.

B.1.4 Comparing models via AIC

One final comparison that can be made for model selection involves the use of the Aikake Information Criterion (AIC). This metric is used to estimate information loss, which we want to minimize with an appropriate model. Therefore, when 2 or more models are compared, the model with lower AIC is preferred. In R, the comparison is done using the `AIC` function.

```
AIC(gam_00, gam_01, gam1)
```

	##		df	AIC
	##	gam_00	3.536147	891.1671
	##	gam_01	4.980481	850.0698
	##	gam1	10.945191	711.4662

The output in this case is expected: model `gam1` has a lower AIC (711.46) whereas the initial two models have higher AICs (891 and 850). The AIC should not be considered as the only estimator of model goodness, instead to be used as complimentary information to the graphical diagnostics and model checks described above.

C GAM and Linear model plots and Missing data

This section covers the code used to generate Figure 3, where the simulated data, fit of the “final” GAM (`gam1`), linear model and GAM on data with missing observations are presented. Note that panel A in Figure 3 and the inlet are generated in the code chunk where the data is simulated in Section B, and are called later to build the figure.

C.1 GAM and Linear model plots

This code chunk creates panels B and D in Figure 3. Note that this code uses the final GAM from the previous section (`gam1`), so the simulated data and the model should be generated before running this section.

```
#linear model
lm1<-lm(St02_sim ~ Day + Group + Day * Group, data = dat_sim)

#creates a dataframe using the length of the covariates for the GAM
gam_predict <- expand_grid(Group = factor(c("Control", "Treatment")),
                          Day = seq(0, 10, by = 0.1),
                          subject=factor(rep(1:10)))

#creates a dataframe using the length of the covariates for rm-ANOVA
lm_predict<-expand_grid(Group = factor(c("Control", "Treatment")),
                        Day = c(0:10),
                        subject=factor(rep(1:10)),
                        )
lm_predict$subject<-factor(paste(lm_predict$subject, lm_predict$Group, sep
= "-"))

#adds the predictions to the grid and creates a confidence interval for
GAM
gam_predict<-gam_predict%>%
  mutate(fit = predict(gam1,gam_predict,se.fit = TRUE,type='response')$
        fit,
        se.fit = predict(gam1, gam_predict,se.fit = TRUE,type='response
        ')$se.fit)

#using lm
lm_predict<-lm_predict%>%
  mutate(fit = predict(lm1,lm_predict,se.fit = TRUE,type='response')$fit
        ,
        se.fit = predict(lm1, lm_predict,se.fit = TRUE,type='response')
        $se.fit)

#plot smooths and confidence interval for GAM
f3<-ggplot(data=dat_sim, aes(x=Day, y=St02_sim, group=Group)) +
  geom_point(aes(color=Group),size=1.5,alpha=0.5,show.legend = FALSE)+
  geom_ribbon(aes( x=Day,ymin=(fit - 2*se.fit),
                ymax=(fit + 2*se.fit),
                fill=Group
                ),
            alpha=0.3,
            data=gam_predict,
            show.legend=FALSE,
            inherit.aes=FALSE) +
  geom_line(aes(y=fit,
                color=Group),
            size=1,data=gam_predict,
            show.legend = FALSE)+
  #facet_wrap(~Group)+
  labs(y=expression(atop(St0[2], 'complete')))+
  scale_x_continuous(breaks=c(0,2,5,7,10))+
```

```

1389     theme_classic()+
1390     theme(
1391       axis.text=element_text(size=22)
1392     )+
1393     scale_color_aaas()+
1394     scale_fill_aaas()
1395
1396 #plot linear fit for rm-ANOVA
1397 f4<-ggplot(data=dat_sim, aes(x=Day, y=St02_sim, group=Group)) +
1398   geom_point(aes(color=Group),size=1.5,alpha=0.5,show.legend = FALSE)+
1399   geom_ribbon(aes( x=Day,ymin=(fit - 2*se.fit),
1400     ymax=(fit + 2*se.fit),fill=Group),
1401     alpha=0.3,
1402     data=lm_predict,
1403     show.legend = FALSE,
1404     inherit.aes=FALSE) +
1405   geom_line(aes(y=fit,
1406     color=Group),
1407     size=1,data=lm_predict,
1408     show.legend = FALSE)+
1409   #facet_wrap(~Group)+
1410   labs(y=expression(paste('St0' [2], ' (simulated)')))+
1411   scale_x_continuous(breaks=c(0,2,5,7,10))+
1412   theme_classic()+
1413   theme(
1414     axis.text=element_text(size=22)
1415   )+
1416   scale_color_aaas()+
1417   scale_fill_aaas()
1418
1419
1420
1421 #posthoc comparisons for the linear model
1422 library(multcomp)
1423
1424
1425 #summary(glht(lm1, linfct = mcp(Group = 'Tukey'))))
1426 #summary(glht(lm1, linfct=mcp(Group="Tukey", interaction_average=TRUE)))
1427

```

C.2 Working with Missing data in GAMs

This code chunk randomly deletes 40% of the total observations in the original simulated data, and then an interaction GAM is fitted. Model diagnostics are presented, and an object that stores the fitted smooths is saved to be called in the final code chunk to build the figure.

```


1432 #missing data
1433 #create a sequence of 40 random numbers between 1 and 100, these numbers
1434   will
1435 #correspond to the row numbers to be randomly erased from the original
1436   dataset
1437 missing <- sample(1:100, 40)
1438

```

```

1440 #create a new dataframe from the simulated data with 40 rows randomly
1441     removed, keep the missing values as NA
1442
1443 ind <- which(dat_sim$StO2_sim %in% sample(dat_sim$StO2_sim, 40))
1444
1445 #create a new dataframe, remove the StO2 column
1446 dat_missing <- dat_sim[,-1]
1447
1448 #add NAs at the ind positions
1449 dat_missing$StO2_sim[ind]<-NA
1450
1451 #Count the number of remaining observations per day (original dataset had
1452     10 per group per day)
1453 dat_missing %>%
1454     group_by(Day,Group) %>%
1455     filter(!is.na(StO2_sim))%>%
1456     count(Day)
1457
1458 ## # A tibble: 10 x 3
1459 ## # Groups:   Day, Group [10]
1460 ##   Day Group      n
1461 ##   <dbl> <fct>   <int>
1462 ## 1     0 Control     2
1463 ## 2     0 Treatment    4
1464 ## 3     2 Control     6
1465 ## 4     2 Treatment    5
1466 ## 5     5 Control     6
1467 ## 6     5 Treatment    4
1468 ## 7     7 Control     3
1469 ## 8     7 Treatment    5
1470 ## 9    10 Control     3
1471 ## 10    10 Treatment    8
1472
1473
1474 #the same model used for the full dataset
1475 mod_m1 <- gam(StO2_sim ~ Group+s(Day,by=Group,k=5), data = dat_missing,
1476     family=scat)
1477 #appraise the model
1478 appraise(mod_m1)
1479
1480

```



```

1481
1482 m_predict <- expand_grid(Group = factor(c("Control", "Treatment")),
1483   Day = seq(0, 10, by = 0.1))
1484
1485 #adds the predictions to the grid and creates a confidence interval
1486 m_predict<-m_predict%>%
1487   mutate(fit = predict(mod_m1,m_predict,se.fit = TRUE,type='response')$
1488     fit,
1489     se.fit = predict(mod_m1, m_predict,se.fit = TRUE,type='response
1490       ')$se.fit)
1491
1492
1493
1494 f6<-ggplot(data=dat_missing, aes(x=Day, y=StO2_sim, group=Group)) +
1495   geom_point(aes(color=Group),size=1.5,alpha=0.5,show.legend = FALSE)+
1496   geom_ribbon(aes( x=Day,ymin=(fit - 2*se.fit),
1497     ymax=(fit + 2*se.fit),
1498     fill=Group
1499   ),
1500     alpha=0.3,
1501     data=m_predict,
1502     show.legend=FALSE,
1503     inherit.aes=FALSE) +
1504   geom_line(aes(y=fit,
1505     color=Group),
1506     size=1,data=m_predict,
1507     show.legend = TRUE)+
1508   #facet_wrap(~Group)+

```

```

1509 labs(y=expression(atop(StO2[2], 'missing')))+
1510   scale_x_continuous(breaks=c(0,2,5,7,10))+
1511   theme_classic()+
1512   theme(
1513     axis.text=element_text(size=22)
1514   )+
1515   scale_color_aaas()+
1516   scale_fill_aaas()
1517

```

```

1518
1519 mult_plot<-f2+inset_element(
1520   f1, left = 0.01,
1521   bottom = 0.5,
1522   right = 0.5,
1523   top = 1.0)+
1524   f3+f4+f6+
1525   plot_annotation(tag_levels='A')&
1526   ylim(c(-5,75)) &
1527   theme(
1528     text=element_text(size=18)
1529   )&
1530   scale_color_aaas()
1531
1532 mult_plot
1533

```




Figure 11: Simulated data and smooths for oxygen saturation in tumors. A: Simulated data that follows previously reported trends (inset) in tumors under chemotherapy (Treatment) or saline (Control) treatment. Simulated data is from a normal distribution with standard deviation of 10% with 10 observations per time point. Lines indicate mean oxygen saturation B: Smooths from the GAM model for the full simulated data with interaction of Group and Treatment. Lines represent trends for each group, shaded regions are 95% confidence intervals. C: rm-ANOVA model for the simulated data, the model does not capture the changes in each group over time. D: Smooths for the GAM model for the simulated data with 40% of its observations missing. Lines represent trends for each group, shaded regions are 95% confidence intervals.